| Issue Date | Title | Author(s) |
| 2022-11 | A multinational Delphi consensus to end the COVID-19 public health threat. | Lazarus, JV; Romero, D; Kopka, CJ; Karim, SA; Abu-Raddad, LJ; Almeida, G; Baptista-Leite, R; Barocas, JA; Barreto, ML; Bar-Yam, Y; Bassat, Q; Batista, C; Bazilian, M; Chiou, S-T; Del Rio, C; Dore, GJ; Gao, GF; Gostin, LO; Hellard, M; Jimenez, JL; Kang, G; Lee, N; Matičič, M; McKee, M; Nsanzimana, S; Oliu-Barton, M; Pradelski, B; Pyzik, O; Rabin, K; Raina, S; Rashid, SF; Rathe, M; Saenz, R; Singh, S; Trock-Hempler, M; Villapol, S; Yap, P; Binagwaho, A; Kamarulzaman, A; El-Mohandes, A; COVID-19 Consensus Statement Panel, |
| 2022-11-07 | Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study. | Conway, A; Read, P; Gilliver, R; McNaughton, T; Valerio, H; Cunningham, EB; Henderson, C; Hadlow, B; Molloy, K; Doab, A; Tillakeratne, S; Pepolim, L; Harrod, ME; Dore, GJ; Grebely, J |
| 2009-09-01 | Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study | Doab, A; Topp, L; Day, CA; Dore, GJ; Maher, L |
| 2016-01-01 | Concordance between missed days of hepatitis B virus anti-viral therapy and virological breakthrough | Sheppard-Law, SJ; Kermeen, M; Holdaway, S; Zekry, A; George, J; Dore, GJ; Maher, L |
| 2008-03-01 | Experience of hepatitis C testing among injecting drug users in Sydney, Australia | Day, CA; White, B; Thein, HH; Doab, A; Dore, GJ; Bates, A; Holden, J; Maher, L |
| 2017-01-01 | Factors associated with HBV virological breakthrough | Sheppard-Law, S; Zablotska-Manos, I; Kermeen, M; Holdaway, S; Lee, A; Zekry, A; Dore, GJ; George, J; Maher, L |
| 2011-04-18 | Predictors of deferral of treatment for hepatitis C infection in Australian clinics | Gidding, HF; Law, MG; Amin, J; MacDonald, GA; Sasadeusz, JJ; Jones, TL; Strasser, SI; George, J; Dore, GJ |
| 2021-07-06 | SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. | Tea, F; Ospina Stella, A; Aggarwal, A; Ross Darley, D; Pilli, D; Vitale, D; Merheb, V; Lee, FXZ; Cunningham, P; Walker, GJ; Fichter, C; Brown, DA; Rawlinson, WD; Isaacs, SR; Mathivanan, V; Hoffmann, M; Pöhlman, S; Mazigi, O; Christ, D; Dwyer, DE; Rockett, RJ; Sintchenko, V; Hoad, VC; Irving, DO; Dore, GJ; Gosbell, IB; Kelleher, AD; Matthews, GV; Brilot, F; Turville, SG |
| 2023-04 | Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study. | Grebely, J; Gilliver, R; McNaughton, T; Conway, A; Cunningham, E; Henderson, C; Hadlow, B; Molloy, K; Doab, A; Tillakeratne, S; Pepolim, L; Harrod, ME; Dore, GJ; Read, P |
